Literature DB >> 20362825

Ligamentization of tendon grafts treated with an endogenous preparation rich in growth factors: gross morphology and histology.

Mikel Sánchez1, Eduardo Anitua, Juan Azofra, Roberto Prado, Francisco Muruzabal, Isabel Andia.   

Abstract

PURPOSE: To investigate whether the application of a particular platelet-rich plasma preparation rich in growth factors (PRGF) during anterior cruciate ligament (ACL) surgery gives a potential advantage for better tendon graft ligamentization.
METHODS: This study included 37 volunteers who underwent either conventional (control group, n = 15) or PRGF-assisted (n = 22) ACL reconstruction with an autogenous hamstring and required second-look arthroscopy to remove hardware or loose bodies, treat meniscal tears or plica syndrome, or resect cyclops lesions at 6 to 24 months after ACL surgery. The gross morphologies of the grafts were evaluated on second-look arthroscopy by use of the full arthroscopic score (0 to 4 points) to evaluate graft thickness and apparent tension (0 to 2 points) plus synovial coverage (0 to 2 points). At the same time, biopsy specimens were harvested uniformly from the grafted tendons. In these specimens the histologic transformation of the tendon graft to ACL-like tissue was evaluated by use of the Ligament Tissue Maturity Index, and a score to assess the progression of new connective tissue enveloping the graft was created by use of 3 criteria previously used to characterize changes during ligament healing: cellularity, vascularity, and collagen properties.
RESULTS: The overall arthroscopic evaluation of PRGF-treated grafts showed an excellent rating in 57.1% of the knees (score of 4) and a fair rating in 42.9% (score of 2 or 3). In contrast, evaluation of untreated grafts showed an excellent rating in 33.3% of the knees, a fair rating in 46.7%, and a poor rating in 20% (score of 0 or 1). Overall, arthroscopic evaluations were not statistically different between PRGF and control groups (P = .051). PRGF treatment influenced the histologic characteristics of the tendon graft, resulting in tissue that was more mature than in controls (P = .024). Histologically evident newly formed connective tissue enveloping the graft was present in 77.3% of PRGF-treated grafts and 40% of controls. The appearance of the connective tissue envelope changed with increasing time from surgery. On the basis of the histologic findings, we suggest that the remodeling of PRGF-treated grafts involves the formation of synovial-like tissue enveloping the graft. This tissue is eventually integrated in the remodeled tendon graft, conferring a similar appearance to the normal ACL.
CONCLUSIONS: The use of PRGF influenced the histologic characteristics of tendon grafts, resulting in more remodeling compared with untreated grafts. We have shown temporal histologic changes during the 6- to 24-month postoperative period of graft maturation, with newly formed connective tissue enveloping most grafts treated with PRGF. LEVEL OF EVIDENCE: Level III, case-control study. Copyright 2010 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362825     DOI: 10.1016/j.arthro.2009.08.019

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  64 in total

1.  Autologous plasma rich in growth factors in the prevention of severe bleeding after teeth extractions in patients with bleeding disorders: a controlled comparison with fibrin glue.

Authors:  Nadia Cocero; Fabrizio Pucci; Maria Messina; Berardino Pollio; Marco Mozzati; Laura Bergamasco
Journal:  Blood Transfus       Date:  2014-10-29       Impact factor: 3.443

2.  Graft-dependent differences in the ligamentization process of anterior cruciate ligament grafts in a sheep trial.

Authors:  Hermann O Mayr; Amelie Stoehr; Markwart Dietrich; Rüdiger von Eisenhart-Rothe; Robert Hube; Senta Senger; Norbert P Suedkamp; Anke Bernstein
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-09-28       Impact factor: 4.342

3.  Cross-sectional area of hamstring tendon autograft after anatomic triple-bundle ACL reconstruction.

Authors:  Kazutaka Kinugasa; Masayuki Hamada; Kenji Yoneda; Tomohiko Matsuo; Tatsuo Mae; Konsei Shino
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-11-19       Impact factor: 4.342

4.  The reharvested patellar tendon has the potential for ligamentization when used for anterior cruciate ligament revision surgery.

Authors:  Sven Stener; Lars Ejerhed; Tomas Movin; Ninni Sernert; Nikos Papadogiannakis; Jüri Kartus
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-02-05       Impact factor: 4.342

5.  The role of platelet-rich plasma in inducing musculoskeletal tissue healing.

Authors:  Brian C Halpern; Salma Chaudhury; Scott A Rodeo
Journal:  HSS J       Date:  2012-01-18

6.  Graft size after anterior cruciate ligament reconstruction.

Authors:  Daniel Hensler; Motoko Miyawaki; Kenneth D Illingworth; Carola F van Eck; Freddie H Fu
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-09-01       Impact factor: 4.342

7.  ACL Study Group survey reveals the evolution of anterior cruciate ligament reconstruction graft choice over the past three decades.

Authors:  Markus P Arnold; Jacob G Calcei; Nicole Vogel; Robert A Magnussen; Mark Clatworthy; Tim Spalding; John D Campbell; John A Bergfeld; Seth L Sherman
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-01-24       Impact factor: 4.342

8.  Updates in biological therapies for knee injuries: tendons.

Authors:  Marco Kawamura Demange; Adriano Marques de Almeida; Scott A Rodeo
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09

Review 9.  Platelet-Rich Plasma Promotes Axon Regeneration, Wound Healing, and Pain Reduction: Fact or Fiction.

Authors:  Damien P Kuffler
Journal:  Mol Neurobiol       Date:  2015-06-06       Impact factor: 5.590

Review 10.  Current Clinical Recommendations for Use of Platelet-Rich Plasma.

Authors:  Adrian D K Le; Lawrence Enweze; Malcolm R DeBaun; Jason L Dragoo
Journal:  Curr Rev Musculoskelet Med       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.